These 4 Penny Stocks On Robinhood Are Anticipating Biotechnology Results This Week
The idea of buying penny stocks tends to hit certain nerves with certain people. On one hand, you have your open-minded traders who are all about making money. Penny stocks, blue-chip stocks, options, etc. are things they likely trade. Then you have those who are starkly against buying these cheap stocks. Unfortunately for them, they are likely a bit short-sighted.
As we’ve seen time and time again, it doesn’t matter the price of the stock, companies aim for success. Rightly so, smaller companies that typically trade as penny stocks are higher risk but can also offer higher rewards as well.
One of the more volatile sectors that personify this has been biotechnology. With small-cap stocks specifically, one announcement can become an incredible catalyst for a move in stock prices. This move can be either up or down and money can be made in either direction.
Last week we went over 5 penny stocks with upcoming results. As many of you saw, these results triggered very short-term catalysts in the market where money was made (and lost) quickly. This is something to keep in mind when analyzing certain penny stocks like these, which will report certain results from trial data.
Penny Stocks To Watch On Robinhood This Week
One of the more popular platforms traders has been using lately to place quick trades: Robinhood. Though there are numerous freemium trading platforms, for those interested in penny stocks, Robinhood continues to take a seat at the top.
Given this fact, trading penny stocks has become more mainstream in 2018 and 2019. Ease of access is a big plus for users. One downside about Robinhood penny stocks is that they are only from companies on the NYSE and NASDAQ.
[Read More] Robinhood Left the Unlimited Margin Glitch Unfixed for Nearly a Year
So if you want to trade OTC penny stocks, Robinhood’s platform may be a bit more restrictive than you’d like. In any case, with this list of penny stocks, we’re looking at several biotech penny stocks that have planned to release material information this week.
Robinhood Penny Stocks To Watch #4: Pieris Pharmaceuticals Inc. (PIRS)
This clinical-stage biotech penny stock focuses on biotherapeutics via its Anticalin® platform. It’s designed for respiratory diseases, cancer, and other diseases. Recently Pieris Pharmaceuticals (PIRS Stock Report) announced a collaboration deal with the labs of the University of Pittsburgh Professors Sally Wenzel, MD and Anuradha Ray, Ph.D. The collaboration focuses on immune phenotyping of asthmatic patients with severe forms of the disease.
“We expect these findings to help us move closer to the goal of defining the endotypes of asthma that require a multipronged approach to understand disease pathogenesis.”
Anuradha Ray, Ph.D
But this isn’t why PIRS stock is one of the penny stocks to watch on Robinhood this week. No, what’s expected this week are results on the company’s Phase I dose-escalation data for its PRS-343.
In the presentation, the company will go over the results of the data in combination with Roche Holdings (RHHBY Stock Report)’s Tecentriq in HER2-positive solid tumors. The date for this data to be presented will be later this week on November 20 so it’s something to keep in mind.
Robinhood Penny Stocks To Watch #3: VBI Vaccines (VBIV)
The next company on this penny stocks watch list VBI Vaccines (VBIV Stock Report) also presents data this week. VBI heads to the Society for Neuro-Oncology in Arizona this week. On Friday, the company plans to go over results from the extension phase of Phase I/IIa trial of a therapeutic CMV vaccine against recurring glioblastoma. We’ve gone over this previously when discussing VBIV stock. The neuro-disease is very debilitating and the company hopes that its treatment platform can address unmet needs.
Specifically, VBI’s VBI-1901 targets two “immunogenic cytomegalovirus antigens.” Essentially, the company’s treatment aims to vaccinate the bodily threat. The current recommended solution is risky surgery along with radiation and chemotherapy. Since GBM is incredibly lethal, it’s become very important to several immunotherapy companies to try and address.
This presentation comes on the heels of the company’s announcement that it begins a Phase 1b/2a study with Brii Biosciences. This trial studies Brii’s BRII-179 (VBI-2601) in patients with chronic hepatitis B infections.
The initial data from this clinical study are expected during the second half of 2020 so this may not be a near term option for a catalyst at the moment. Either way, it’s something good to keep in mind and follow if VBIV stock is on your personal watch list.
Robinhood Penny Stocks To Watch #2: Delmar Pharmaceuticals (DMPI)
This penny stock was one that continues to hit penny stocks watch lists this month. Delmar Pharmaceuticals (DMPI Stock Report) has been on the move since hitting 52-week lows of $0.402 during the first half of October. Since then, shares of DMPI stock have rallied as much as 114% with highs of $0.8599 this month so far.
The company has presented data at several conferences over the last few months. This week is no different. The biotech company presents updates on 2 Phase 2 trials of VAL-083. The 2019 Society for NeuroOncology Annual Meets will see the company discuss its therapy as a first-line treatment. It also goes over updates on enrollment, safety, and efficacy.
Read More
- 3 Penny Stocks To Trade On Friday? 1 Up Over 390% This Year
- Are Penny Stocks Worth It? These 3 Hit New Highs This Week
- 5 Penny Stocks To Buy For Under $2 Right Now
VAL0983 is designed as a “first-in-class” chemotherapeutic that has shown the ability to fight a range of cancers. These include ovarian, solid tumors, and central nervous system cancers. Similar to VBI, Delmar presents on Friday so we’ve got all week to watch what happens in the market. Will DMPI stock score another big win?
Robinhood Penny Stocks To Watch #1: Affimed (AFMD)
Unlike the other stocks on this list, Affimed (AFMD Stock Report) expects results of a different kind. This week the company reports earnings. Tuesday morning before the open, Affimed will delivery its financials to the market. Shares of AFMD stock haven’t weathered the storm too well this month. It dropped hard after announcing a $34.5 million offering. Shares were sold at a price of $2.50 so it makes sense as to why AFMD currently sits at $2.47.
What’s interesting is that the company will be presenting a general overview of its operations 1 day after reporting earnings. The Jefferies 2019 London Healthcare Conference starts Wednesday.
Company CEO Dr. Adi Hoess present at 10:20 AM EST, which is obviously right in the thick of the morning session on that day. What we’ll be paying closer attention to is not only earnings results but also how investors react to Affimed’s presentation in London.
The company works to address certain cancers. Its ROCK® platform allows the design of specific cell engagers for a given patient population. The Company is developing single and combination therapies to treat hematologic and solid tumors. And as you’ve probably realized from reading the “about us” from the other companies, cancer is a big deal.
